Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma (Q45143413)
Jump to navigation
Jump to search
scientific article published on 21 January 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma |
scientific article published on 21 January 2013 |
Statements
1 reference
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma (English)
1 reference
1 reference
Bernard Escudier
1 reference
Jose A Lopez-Martin
1 reference
Chia-Chi Lin
1 reference
Jürgen E Gschwend
1 reference
Andrea Harzstark
1 reference
Daniel Castellano
1 reference
Paramita Sen
1 reference
Julie Chang
1 reference
Michael Shi
1 reference
Andrea Kay
1 reference
21 January 2013
1 reference
1 reference
Identifiers
1 reference